Robert Azelby

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Dublin, OH
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Robert Azelby
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert Azelby

Form 4 holding President & CEO, Director

Eliem Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
500,000
Estimated value
Report date
31 Oct 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Autolus Therapeutics plc

Security class
Share Option (Right to Buy)
Shares / value
47,500
Estimated value
Report date
29 Jun 2026
Price
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
Form 4 holding Director

Clovis Oncology, Inc.

Security class
Stock Option (right to buy)
Shares / value
42,223
Estimated value
Report date
10 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Autolus Therapeutics plc

Security class
Restricted Share Units
Shares / value
31,667
Estimated value
Report date
29 Jun 2026
Price
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
Form 4 holding Director

CHINOOK THERAPEUTICS, INC.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
11 Aug 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

CHINOOK THERAPEUTICS, INC.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
11 Aug 2023
Price
$26.12
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Robert Azelby

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .